Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients

Phase 4

Withdrawn

• Conditions: Delirium
• Interventions: Drug: Sevoflurane; Drug: Dexmedetomidine; Drug: Propofol

• Registration Number: NCT02394418
• Lead Sponsor: Moscow Regional Research and Clinical Institute (MONIKI)

Brief Summary

Assessment of sedative effects of sevoflurane, dexmedetomidine and propofol on the clinical course of delirium, SIRS and neuroinflammation in mechanically ventilated patients using CAM-ICU scale, GSK-3beta and protein S100b in serum.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-01-27
• Study First Submitted QC: 2015-03-16
• Study First Posted: 2015-03-20
• Study Start: 2017-09-01
• Primary Completion: 2018-05
• Study Completion: 2018-08
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-13
• Last Update Posted: 2019-08-15

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• presence of delirium

Exclusion Criteria

• presence of Alzheimer's disease
• any mental disorder
• presence of cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Sevoflurane	Sevoflurane	Treatment of delirium by inhaled sevoflurane
Dexmedetomidine	Dexmedetomidine	Treatment of delirium by dexmedetomidine i.v. infusion
Propofol	Propofol	Treatment of delirium by propofol i.v. infusion

Primary Outcome Measures

Name	Time	Method
Duration of Delirium	up to 5 days	Delirium assessment by CAM-ICU scale

Secondary Outcome Measures

Name	Time	Method
Change of protein S100b in serum	from delirium onset up to 5 days
Change of GSK-3beta in serum	from delirium onset up to 5 days